SCHEMBL830344

SCHEMBL830344

CC1CC(C)CN(C(=O)Nc2ccc3ccccc3c2Br)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.57
ALDH1A1 P00352 6/20 0.48
HSD17B10 Q99714 5/20 0.48
TAAR1 Q96RJ0 1/20 0.43
TSHR P16473 1/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 2/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829234 0.85 KDM4E (0.57) KDM4EALDH1A1HSD17B10TAAR1TSHR
SCHEMBL830020 0.84 KDM4E (0.67) KDM4EALDH1A1HSD17B10TAAR1TSHR
SCHEMBL829713 0.79 RAB9A (0.56) KDM4EALDH1A1HSD17B10TAAR1TSHR
SCHEMBL828885 0.75 NCEH1 (0.67) KDM4EALDH1A1TSHRKMT2ASMN1; SMN2
SCHEMBL829706 0.75 KDM4E (0.73) KDM4EALDH1A1HSD17B10TSHRKMT2A
SCHEMBL830019 0.74 KDM4E (0.62) KDM4EALDH1A1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL7478284 0.73 RXFP1 (0.60) KDM4EALDH1A1KMT2ASMN1; SMN2POLB
SCHEMBL31152642 0.73 RXFP1 (0.60) KDM4EALDH1A1KMT2ASMN1; SMN2POLB
SCHEMBL829549 0.73 FAAH (0.61) KDM4EALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL829045 0.72 ALDH1A1 (0.50) KDM4EALDH1A1HSD17B10TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 KDM4E 358/4885ALDH1A1 936/4885HSD17B10 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.